期刊文献+

Twist对EMT调控在循环肿瘤细胞监测与抗癌药物评价中的临床意义 被引量:6

Twist regulation of EMT and its clinical significance in monitoring circulating tumor cells and evaluating effects of anticancer drugs
在线阅读 下载PDF
导出
摘要 肿瘤细胞的上皮间质可塑性变化包括上皮-间质化(epithelial-mesenchymal transition,EMT)和间质-上皮转化(mesenchymal-epithelial transition,MET)的可逆过程,在循环肿瘤细胞(circulating tumor cells,CTCs)形成、转归及肿瘤转移过程中起到重要作用。Twist在人横纹肌肉瘤、乳腺癌、胃癌等多种肿瘤中过表达,肿瘤细胞中Twist与多种信号通路连接,形成复杂的网状环路参与调控CTCs中EMT/MET的发生并促进肿瘤细胞向远处转移。因此,通过监测CTCs中Twist本身以及所调控的上皮-间质表型分子标志物的变化,不仅可以增加肿瘤标志物CTCs的检出率,提供肿瘤临床分期及预后评估的直接证据;而且,对于评估多种抗肿瘤药物的疗效及耐药机制均具有重要的临床意义。 Tumor cell plasticity, including epithelial to mesenchymal transition (EMT) and its reverse program, mesenchymal to epithelial transition (MET), regulates circulating tumor cells and carcinoma metastasis. Twist is overexpressed in rhabdomyosarcoma, breast cancer, gastric cancer, and other tumors. Twist, as a transcriptional factor, cross-talks with multiple signaling pathways, forming a complex network to participate in the regulation of EMT/MET in circulating tumor cells, which in turn promotes metastasis of tumor cells. Therefore, monitoring the level of Twist and epithelial - mesenchymal phenotypic molecules is important as it may be beneficial for increasing the detection ratio of circulating tumor cells as tumor biomarkers and for evaluating the effects of anticancer drugs.
作者 李文卿 丁怡 姜雨 路中 王丽华 Wenqing LI Yi DING Yu JIANG Zhong LU Lihua WANG(Laboratory of Molecular Oncology, Affiliated Hospital, Weifang Medical College, Weifang 261053, China)
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2016年第17期770-774,共5页 Chinese Journal of Clinical Oncology
基金 国家自然科学基金项目(编号:81472489) 山东省科技发展计划项目(编号:2014GSF118040)资助~~
关键词 TWIST 上皮-间质转化 循环肿瘤细胞 肿瘤标志物 抗肿瘤药物 Twist, epithelial-mesenchymal transition, circulating tumor cells, tumor biomarkers, anticancer drugs
  • 相关文献

参考文献43

  • 1Montserrat N, Gallardo A, Escuin D, et al. Repression of E-cadherin by SNAIL, ZEB1, and TWIST in.invasive ductal carcinomas of the breast: a cooperative effort[J]? Hum Pathol, 2011, 42(1):103-110.
  • 2Thisse B, El Messal M, Perrin-Schmitt F. The twist gene: isolation of a Drosophila zygotic gene necessary for the establishment of dorso- ventral pattern[J]. Nucleic Acids Res, 1987, 15(8):3439-3453.
  • 3Franco HL, Casasnovas J, Rodriguez-Medina JR, et al. Redundant or separate entities? roles of Twist1 and Twist2 as molecular switches during gene transcription[J]. Nucleic Acids Res, 2011, 39(4):1177- 1186.
  • 4Chang A T, Liu Y, Ayyanathan K, et al. An evolutionarily conserved DNA architecture determines target specificity of the TWIST family bHLH transcription factors[J]. Genes & development, 2015, 29(6): 603-616.
  • 5Puisieux A, Valsesia-Wittmann S, Ansieau S. A twist for survival and cancer progression[J]. Br J Cancer, 2006, 94(1):13-17.
  • 6Norozi F, Ahmadzadeh A, Shahjahani M, et al. Twist as a new prog- nostic marker in hematological malignancies[J]. Clin Transl Oncol, 2016, 18(2):113-124.
  • 7Je EC, Lca BS, Ga GA. The role of transcription factor TWIST in can- cer cells[J]. J Genet Syndr Gene Ther, 2013, 4:124.
  • 8Mordor's K, Haapasalo J, Makela K, et al. Twist predicts poor out- come of patients with astrocytic glioma[J]. J Clin Pathol, 2015, 68 (11):905-912.
  • 9Huang Y, Meng T, Wang S, et al. Twist1- and Twist2-haploinsuffi- ciency results in reduced bone formation[J]. PLoS One, 2014, 9(6): e99331.
  • 10Marchegiani S, Davis T, Tessadori F, et al. Recurrent mutations in the basic domain of TWIST2 cause AblepharonMacrostomia and Barber-Say syndromes[J]. Am J Hum Genet, 2015, 97(2):99-110.

二级参考文献51

  • 1Gennari A, Stockler M, Puntoni M, et al. Duration of chemo- therapy for metastatic breast cancer:a systematic review and me ta-analysis of randomized clinical trialsEJ3. J Clin Oncol, 2011, 29(16) :2144 2149,.
  • 2Swaby RF, Cristofanilli M. Circulating tumor cells in breast cancer: a tool whose time has come of ageEJ3. BMC Meal, 2011,9.-43.
  • 3Lianidou ES, Strati A, Markou A. Circulating tumor ceils as promising novel biomarkers in solid cancersEJ3. Crit Rev Clin Lab Sci, 2014, 51(3) ~160-171.
  • 4Riahi R, Gogoi P, Sepehri S, et al. A novel microchannel-based device to capture and analyze circulating tumor cells (CTCs) of breast cancer~J3. Int J Oncol, 2014, 44(6) =1870-1878.
  • 5Breitenbuecher F, Hoffarth S, Worm K, et al. Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancerpatientsFJ~. PloSOne, 2014, 9(1):e85350.
  • 6Lou J, Ben S, Yang G, et al. Quantification of rare circulating tumor cells in non-small cell lung cancer by ligand targeted PCR[J]. PloSOne, 2013, 8(12):e80458.
  • 7Steinert G, Seholch S, Niemietz T, et al. Immune escape and survival mechanisms in circulating tumor cells of colorectal canc- er[J]. CancerRes, 2014,74(6):1694-1704.
  • 8Groot Koerkamp B, Rahhari NN, guchler MW, et al. Circulat ing tumor cells and prognosis of patients with resectable colorec tal liver metastases or widespread metastatic eolorectal cancer: a meta-analysis[J]. Ann Surg OncoI, 2013,20(7)~2156 2165.
  • 9Tjensvoll K, Nordgard O, Smaaland R. Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications[J]. Int J Cancer, 2014,134(1) : 1-8.
  • 10Cen P, Ni X, Yang J, et al. Circulating tumor cells in the diag- nosis and management of pancreatic cancer[J]. Biochim Biophys Acta, 2012,I826(2) :350-356.

共引文献28

同被引文献53

引证文献6

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部